Mydecine Innovations Group Inc MYCOF:OTCPK

*Data is delayed | Exchange | USD
Last | 1:03 PM EDT
0.0126quote price arrow up+0.0015 (+13.5135%)
Volume
250
52 week range
0.00 - 0.29
Loading...
  • Open0.0126
  • Day High0.0126
  • Day Low0.0126
  • Prev Close0.0111
  • 52 Week High0.29
  • 52 Week High Date05/08/23
  • 52 Week Low0.00
  • 52 Week Low Date04/04/24

Key Stats

  • Market Cap905,506.88
  • Shares Out61.76M
  • 10 Day Average Volume1,655.43
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.44

KEY STATS

  • Open0.0126
  • Day High0.0126
  • Day Low0.0126
  • Prev Close0.0111
  • 52 Week High0.29
  • 52 Week High Date05/08/23
  • 52 Week Low0.00
  • 52 Week Low Date04/04/24
  • Market Cap905,506.88
  • Shares Out61.76M
  • 10 Day Average Volume1,655.43
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.44

RATIOS/PROFITABILITY

  • EPS (TTM)-0.78
  • P/E (TTM)-0.02
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mydecine Innovations Group Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at...
David Bartch
President, Chief Executive Officer, Director
Damon Michaels
Chief Operating Officer
John Ross
Chief Financial Officer
Address
1890-1075 West Georgia Street
Vancouver, BC
V6E 3C9
Canada